No, Your Prognosis is NOT Hopeless
Your mixed connective tissue disease-associated inflammatory myositis is a treatable condition with favorable outcomes when managed appropriately, and your G6PD deficiency simply requires avoiding specific medications—particularly methylene blue—but does not fundamentally alter your myositis prognosis. 1, 2
Understanding Your Myositis Prognosis
The evidence shows that MCTD-associated myositis generally responds well to treatment. Recent data demonstrates that therapeutic responses are consistently favorable overall with no deaths during observation periods in MCTD myositis cohorts 2. While you may experience muscle weakness that could require intensive therapy, this is manageable with appropriate immunosuppression.
Expected Disease Course
Your prognosis breaks down into three possible trajectories 3, 4:
- One-third of MCTD patients: Enter long-term remission with anti-U1-RNP antibodies disappearing
- 45% achieve remission after median follow-up of 8 years 4
- One-third: Experience persistent but manageable morbidity (arthritis, fatigue, dyspnea)
- One-third: Have severe progressive disease—but this is NOT a death sentence
The most critical point: Only 5.6% mortality rate in large cohorts, and only 25.8% progress to a differentiated connective tissue disease 4.
Your Treatment Algorithm
Initial therapy 1:
High-dose corticosteroids (prednisone 0.5-1 mg/kg/day) concurrent with steroid-sparing agent
Choose ONE steroid-sparing agent:
- Mycophenolate mofetil: 500 mg twice daily, increase by 500 mg weekly to 1000 mg twice daily (preferred given your G6PD deficiency)
- Azathioprine: 2 mg/kg ideal body weight (requires thiopurine methyltransferase testing first)
- Methotrexate: Start 15 mg weekly, target 25 mg weekly with 1 mg/day folic acid
Taper prednisone every 2 weeks following this schedule: 60→40→30→25→20→17.5→15→12.5→10→7.5→5→2.5 mg/day 1
If You Have Severe Disease Features
If you present with severe weakness limiting self-care, dysphagia, or very elevated creatine kinase (>10x normal) 2, 5:
- High-dose methylprednisolone IV (1-2 mg/kg or pulse therapy)
- Add IVIG (intravenous immunoglobulin)
- Consider rituximab if no improvement after 2 weeks 6
- Alternative: cyclophosphamide, cyclosporine, or TNF-α/IL-6 antagonists 1
Critical G6PD Considerations
Your G6PD deficiency creates ONE major treatment restriction 7:
ABSOLUTELY AVOID METHYLENE BLUE - This drug can cause:
- Severe hemolytic anemia
- Paradoxical worsening of methemoglobinemia
- Heinz body formation
This is only relevant if you develop methemoglobinemia (which is unlikely in myositis treatment). For methemoglobinemia in G6PD deficiency, use ascorbic acid (vitamin C) instead: 0.5-10 g IV depending on severity 7.
Your standard myositis medications are safe: Corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, IVIG, and rituximab do NOT cause problems with G6PD deficiency.
What to Monitor
Track these markers to assess your response 1:
- Creatine kinase (CK) levels - should normalize with treatment
- Muscle strength - proximal and any atypical weakness (face, neck, wrist, fingers)
- Inflammatory markers (ESR, CRP)
- Myositis-specific autoantibodies - may predict organ involvement and long-term prognosis
Common Pitfalls to Avoid
Don't accept inadequate treatment: If you have severe myositis with very elevated CK or extensive weakness, you need aggressive therapy upfront—not just oral prednisone 2, 5. Two case reports emphasize that severe MCTD myositis can be refractory to initial corticosteroids alone and requires escalation 5, 8.
Watch for cardiac involvement: MCTD can affect the heart. If you develop dyspnea, get troponin, ECG, and echocardiogram 6, 9.
Monitor for pulmonary hypertension: This is the most severe manifestation contributing to premature death in MCTD (7.6% prevalence), though it's typically associated with vascular abnormalities rather than your myositis 3, 4.
The Bottom Line
Your condition is serious but highly treatable. The combination of MCTD myositis with G6PD deficiency does NOT create a hopeless situation—it simply means you need appropriate immunosuppression while avoiding one specific drug (methylene blue) that you're unlikely to encounter in myositis treatment anyway. Most patients achieve remission or well-controlled disease 2, 4.